The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
yeap correct, thoughmyou were referring to the mologic results as what he picked up on first.
Thanks eazy, the visitect test is truly a world class product which in short term should attract a premium.
Innova’s one*…that damn autocorrect
Megatro I think Twatch got confused and thought I was talking about the mologic antigen test stats being new…when i was referring to the new study published on 7th may on the innova test, which clarifies that our Visitect test is superior to innova’ some :)
Easy I don't remember seeing that either and have in fact been looking for it elsewhere previously.
Twatch - Must of missed that bit…document was released Friday 7th may…
I don’t remember anything being mentioned about the innova study on Friday?
picked it up first ??, it was discussed on here last week !
The guys on Twitter been doing some good research today…before I move on just giving credit to @tom_the_bomb__ as he picked it up first as far as I’m aware..he didn’t post the link to source so that’s why I’m not posting his tweet…
Looks like our Visitect(Mologic) Antigen is ‘best in class’ with: 100% specificity 96.4% sensitivity in a study with 665 people…
“The Innova SARS-CoV-2 AG test, currently used by NHS Test and Trace had results from six studies involving 3904 participants, of which 1017 were positive cases. The range of results across these studies varied from 28.3-78.8% sensitivity and 99.6-99.8% specificity. Sensitivity was highest when used by laboratory scientists (78.8%) and lower when used by self-trained non-healthcare workers (57.5%).”
https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-22-march-2021/freedom-of-information-request-about-lateral-flow-tests-and-covid-19-vaccines-foi-21231